AIDS Community Research Initiative of America (ACRIA) - Fall 2003 / Winter 2004

The protease inhibitors, or PIs, work at a later stage in the HIV life cycle than the NRTIs and NNRTIs. Once HIV's genetic material has been changed from RNA to DNA and is integrated into the DNA in the cell's nucleus, the cell produces a long chain of genetic material (proteins and enzymes). HIV's protease enzyme acts like a pair of scissors, cutting the chain into smaller pieces which then come together to form new copies of the virus.

Protease inhibitors attach to the protease enzyme and keep it from cutting the long chain of proteins and enzymes into smaller pieces - they block the scissors. HIV is unable to package itself into new infectious virus. When a PI is combined with other antiretrovirals - usually two NRTIs - the rate of HIV replication can be slowed down dramatically.

To varying degrees, PIs have been associated with certain long-term side effects, including increased blood sugar levels, insulin resistance, elevated cholesterol and triglyceride levels, osteonecrosis (death of bone tissue), and osteoporosis (a decrease in bone mineral density). Some of these conditions may increase a person's risk of heart disease, diabetes, and bone fractures. PIs have also been linked to various types of fat redistribution, which may be part of a larger syndrome involving changes in people's metabolism as a result of HIV disease, antiretrovirals used to treat HIV (not only the PIs), or both.

PIs have considerable drug interactions - between each other, with non-nucleosides, and with many drugs used to treat other conditions. For example, each of the PIs interacts with the anti-tuberculosis drug rifampin, Viagra (sildenafil), St. John's wort, and a long list of other drugs. Be sure to talk to your healthcare provider about other medications you're taking, including over-the-counter treatments, herbs, and supplements.

Complete resistance to some of the PIs can develop as a result of just one mutation (change) in HIV's protease enzyme, such as the D30N mutation for Viracept (nelfinavir) or the I50V mutation for Agenerase (amprenavir). But with most of the PIs, it takes several mutations for complete resistance to develop. Partial or complete resistance to one PI can cause partial or complete cross-resistance to other PIs.

20030910
CR030912

Copyright © 2003 - AIDS Community Research Initiative of America. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, ACRIA Update, 230 West 38th Street, 17th Floor, New York, NY 10018; (212) 924-3934; Fax (212) 924-3936 .

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. ÆGIS. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS, or the party credited as the provider of the content.